VolitionRX Ltd’s recent filing unveils that its President and CEO Reynolds Cameron John acquired Company’s shares for reported $9885.0 on Sep 12 ’25. In the deal valued at $0.66 per share,15,000 shares were bought. As a result of this transaction, Reynolds Cameron John now holds 2,624,847 shares worth roughly $1.78 million.
Then, Innes Guy Archibald bought 78,125 shares, generating $50,000 in total proceeds. Upon buying the shares at $0.64, the Director now owns 966,814 shares.
Before that, Reynolds Cameron John bought 78,125 shares. VolitionRX Ltd shares valued at $50,000 were divested by the President and CEO at a price of $0.64 per share. As a result of the transaction, Reynolds Cameron John now holds 2,609,847 shares, worth roughly $1.77 million.
H.C. Wainwright initiated its VolitionRX Ltd [VNRX] rating to a Buy in a research note published on April 08, 2025; the price target was $2.50. A number of analysts have revised their coverage, including The Benchmark Company’s analysts, who decreased its forecast for the stock in early February from “a Buy” to “a Hold”. Cantor Fitzgerald started covering the stock on March 10, 2021. It rated VNRX as “an Overweight”.
Price Performance Review of VNRX
On Friday, VolitionRX Ltd [AMEX:VNRX] saw its stock jump 8.96% to $0.68. Over the last five days, the stock has gained 3.64%. VolitionRX Ltd shares have risen nearly 3.82% since the year began. Nevertheless, the stocks have risen 13.33% over the past one year.
How much short interest is there in VolitionRX Ltd?
A steep rise in short interest was recorded in VolitionRX Ltd stocks on 2025-08-29, growing by 0.11 million shares to a total of 0.3 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 0.19 million shares. There was a rise of 36.72%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 16, 2018 when Maxim Group began covering the stock and recommended ‘”a Buy”‘ rating along with a $6 price target.
